Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25p -0.44% 56.00p 55.00p 57.00p 56.25p 56.00p 56.25p 33,711 09:43:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -4.5 -3.7 - 67.55

Futura Medical (FUM) Latest News

More Futura Medical News
Futura Medical Takeover Rumours

Futura Medical (FUM) Share Charts

1 Year Futura Medical Chart

1 Year Futura Medical Chart

1 Month Futura Medical Chart

1 Month Futura Medical Chart

Intraday Futura Medical Chart

Intraday Futura Medical Chart

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
23/5/201717:33FUTURA a winner for 20152,818
08/5/201710:53www.bluediamondcondom.com50
02/12/201613:27FUM delivering on sex,pain and rock'n'roll11,414
21/6/201608:43fum reality1
07/11/201412:19fum-

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:13:2155.304,0002,212.00O
11:05:0055.306535.95O
10:00:4156.5010,0005,650.00O
09:07:5656.202,6461,487.05O
08:51:3655.755,0002,787.50O
View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

DateSubject
24/5/2017
09:20
Futura Medical Daily Update: Futura Medical is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 56.25p.
Futura Medical has a 4 week average price of 51p and a 12 week average price of 49p.
The 1 year high share price is 96.25p while the 1 year low share price is currently 17.50p.
There are currently 120,628,682 shares in issue and the average daily traded volume is 239,432 shares. The market capitalisation of Futura Medical is £67,552,061.92.
19/5/2017
09:00
jamesd888: what would the share price be if we not an RNS for additional licensing deals for TIB200 (tropical ibuprofen).....95p before the AGM
27/3/2017
11:41
loobrush: from iii What is the future for Futura's share price. I have detailed below, from info in the results and more particularly from the webcast presentation (which not many may have seen-but now available on their website) what news Futura expects to announce during 2017, of which there is quite a lot. MED2000-Securing of major commercial deal. CSD500-Church & Dwight launch in selected markets(probably UK, France & Germany ) CSD500-Launch in 6 more countries and possibly up to 13. TPR100 & TIB200 -securing of further deals in USA/Europe. So what about the share price. Clearly there is massive potential if all the products end up all on sale at once but leading up to that point I think that announcements of each of the above this year will increase the share price as each one will confirm that progress is being made, some more than others. Clearly with any deal being announced one can expect upfront deal fees which can be substantial and this is what Futura expect as they stated at the results seminar they have no need to raise further cash. Looking at other company deals in these sectors the total upfront fees could easily be in the £25-40 million range. So what could Futura be worth in a couple of years time. From global sales figures provided by Futura we have the following peak potential for Futura's market share and earnings. MED 2000 ($1 billion per annum)= £800 million say @5% royalty is £40 million pa TPR100 & TIB200 (1/2 billion per annum)=£400 million say @5% royalty is £20 million pa CSD500 @10% market share of a $6billion pa market is $600 million=£450 million @ 5% royalty rate is £9 million per annum. That totals to £69 million per annum. That's the peak potential. Lets discount that by 1/2 that gives £34.5 million per annum. So with an income of that size with minimal overheads the company on a p/e of 8 would be valued at £552 million or 460p per share Current company value@53p is £63million So the potential is 9 times the current share price. With lots of news this year we could easily see the share price double up with the newsflow and big bucks coming after the MED 2000 trial results in a year or so. Price may drift a bit before the first news but as news may come at any time so it's a hold or buy at this price in my view. Also there may be a surprise announcement of a new product(s) as they are working on this at the moment.
23/3/2017
13:43
j777j: Motley Fool.....Growth star in the making?Turning to the growth front, Futura Medical (LSE: FUM) is a possible pharmaceuticals and biotechnology winner with interesting prospects.It's big in the field of erectile dysfunction with its Eroxon candidate having "the potential to be the world's fastest-acting treatment for ED", and its aspirations are supported by a "novel erectogenic condom". Oh, and it does pain-relief stuff too.The erectile dysfunction gel is certainly good at getting the share price up - it caused a surge back in September 2016 when Futura announced "breakthrough results" from early trials and spoke of a potential $5bn market. Thursday's full-year update continued the enthusiasm, telling us the firm intends to "begin a Phase III placebo-controlled parallel group multi-centre clinical study of 700 or more patients in Q4 2017?.An investment in a company like this, which is not generating profits yet, is definitely not to be undertaken lightly. Indeed, far from a profit, Futura recorded a net loss of £3.7m for the year - though that is down from 2015's loss of £5.08m, thanks to lower spending on clinical trials.On the bright side, a share placing in November raised £12m for the coffers, and at 31 December the company had cash resources of £12.35m.That looks like a reasonably healthy position to me at this stage in the company's development, but medical progress can be painfully slow and we really can't tell how long it will be (assuming a successful Phase III and eventual clinical approval) before sales start ramping up enough to achieve profits.So Futura Medical is still a risky investment, but if you can live with that I'd say it's one of the more promising of its kind that I've seen recently.
21/3/2017
13:59
bull sykes: From FUM Interim Results published 13.09.2016. Bottom of Page 3 - "Commercial manufacture of product for the launch of CSD500 in the first Middle East country, where regulatory approval has already been granted, has already taken place with the launch expected later this year. The initial royalty payment has already been received for this and will be recognised upon launch. We anticipate further launches of the product in other territories during 2017." End Quote. CSD500 recently launched in Saudi-Arabia, so I am assume 'recognised upon launch' to mean that royalty payments will be visible in the accounts. Hopefully there will be info about amount of initial sales. 1) It will show the market FUM has a royalties income stream for the first time. 2) It might prompt the business press to articulate more often on FUM progress, and help to stabilise /improve the share price. I posted the above on another board recently. It just remains for the market to be satisfied with the numbers..
07/2/2017
16:07
sportbilly1976: Further to my post earlier, I rang FUM. Message taken and I've just had a call back. Essentially all is okay with progress on multiple fronts (commercialisation deals etc)but they are disappointed with the recent share price fall Understand that the fall in share price recently nothing more than retail selling pressure. They are currently looking to build the institutional shareholder base. Two announcements this year not had the impact they might have hoped, but down to the vagaries of the market. It was also mentioned that the LSE have contacted the Company over the fall, but nothing material & undisclosed behind the fall Lack of "we know of no reason..." rns - essentially striking a balance between allowing the market to function and appearing defensive with any announcement to reassure shareholders On the back of the call I am reassured to continue to hold and will look to add when funds allow at these levels
07/2/2017
10:49
sportbilly1976: It is these scenarios which I find it odd that the LSE doesn't require any communication form the Company as to clarify if there is a reason.... ...yet when the share price rises in a similar manner a "We know of no reason....." rns pops up!! Maybe the Company could be contacted by a few of us pi's to request a "We know of no reason for the recent fall in the share price" rns! :)
04/1/2017
08:50
greedfear: Yes, good deals take time. People investing in these kind of ventures should know that expectations are just that, expectations. Patience is often needed (sometimes having trouble there myself) but the wait is often worth it. I'm very confident the share price will increase >100% this year. Just too much going on. Also I believe FUM to be a take over target for big pharma at a price that would be multiples of the current share price.
16/11/2016
12:37
loobrush: Med2002 has the potential for a double whammy with over the counter(OTC) for low dose and prescription only for the high dose.I don't know which will be biggest,but it seems to me that the OTC version could be miles bigger as people will try this whether they have a problem or not.If the OTC version was put on sale now a lot of men would try it just to see what happens let alone those with a problem who dont want to see a doctor.FUM'S value is certainly higher than todays share price and my own valuation if the final trial goes well is that the share price will be over £3.00 by this time next year. Next we should hear first launch news on CSD500 before Xmas and European manufacturing approval-then into next year further launches across the globe-so plenty of news coming to and as things progress share price will move up accordingly.
26/11/2015
15:03
lbo: That is a fair criticism in light of the disappointing share price performance. But I remember no shareholders proposed any resolutions at the AGM regarding the Board, its remuneration or share price performance? Why is that? I do remember one or two posters on here said they gave the Board a hard time in Q&A but I did not see any sign of shareholders looking for change on the Board of Directors. So it would seem to me more would be gained by asking shareholders why they are seemingly happy with progress and the share price and taking no action. Or maybe most on here are not even shareholders anymore but disgruntled small PIs who invested when Futura was overhyped and are now very bitter. I do recollect a lot of posters on here linked to Iofina which I also see was even more overhyped. So this Q&A now would be more of an informative and elightening process. We have even had Hendersons increasing their shareholding during this time. Why have they taken a seemingly opposing view of support? Is it because they are buying in at more realistic valuation and after more real progress has been made in products terms? But perhaps the support for the Board will change by the time of the next AGM or even before if the share price does not perform as well as the faith Mr Barder seems to continue to have in Futura. Time will tell who is right and who is wrong and who will be rewarded by showing support or who may suffer irrecoverable financial loss. I would also say that it might be unfair to say he has not a lot to loose also now. Because if he does not perform by the next AGM in terms of share price then he will surely be seen by all as having failed and not just by shareholders. And by this I refer to his own family who I believe also have a substantial shareholding and vested interest in Futura.
13/11/2013
09:39
sceptic bull: Looking to get back into the small cap markets and I like the look of FUM as one of many many candidates to invest. Attractions: The product will sell itself regardless of marketing ability of partner with plenty of mainstream media coverage. Low cost base of Company therefore any funding will not be significant. If the product works as described then it will get a good % of the market The IP. The main players would have tried very hard to produce their own in-house OTC product but clearly they haven't been able to. Eddison's market share projections and target share price look conservative. Question marks Trial was quite limited. 100 participants. Why no follow up trial to assist marketing claims? How conclusive was the trial? I doubt if this is a big issue but a further conclusive trial would have given me more confidence. If this product works then FUM will get a very significant share of the market. Why did RB relinquish? Not especially important as big companies can make silly decisions. Drop in share price. Are FUM doing a placing? Markets for funding small caps usually exact a discount. Although if reason for drop is some placing leak then I doubt it has further to fall. Despite being in control of production issues FUM cannot control launch date for CSD Limited progress on pain relief products so FUM share price is very reliant on CSD500 Any potential competition. Unlikely as there has been plenty of time to produce something. How good is the board of directors and especially the CEO? Seems competent but not over inspiring.
Futura Medical share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:35 V: D:20170524 11:36:42